RA Capital Management 13F holdings, Q4 2018
Holdings as of December 31, 2018 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 25 US equity positions worth $1.7bn in its Q4 2018 13F filing. The largest position was WVE at 18.4% of the reported book, followed by ASND and SYNTHORX INC. Against the Q3 2018 filing, it opened 4 new positions, added to 9 and reduced 2 among the top 25 holdings.
What did RA Capital Management own in Q4 2018? Top 25 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2018 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 18.4% | $315.8m | 7,512,049 | 0% | held |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 15.5% | $265.7m | 4,240,536 | 0% | held |
| 3 | SYNTHORX INC | 9.8% | $169.0m | 9,724,598 | – | new | |
| 4 | ZOGENIX INC | 5.1% | $86.9m | 2,382,168 | 27% | added | |
| 5 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 5.0% | $86.0m | 10,660,349 | 15% | added |
| 6 | ORCHARD THERAPEUTICS PLC | 4.4% | $76.2m | 4,845,933 | – | new | |
| 7 | INFLARX NV | 4.4% | $75.8m | 2,085,089 | 6% | added | |
| 8 | SLDB SOLID BIOSCIENCES INC | 4.2% | $72.1m | 2,689,444 | 0% | held | |
| 9 | MYOVANT SCIENCES LTD | 3.5% | $60.9m | 3,711,549 | 8% | added | |
| 10 | EIDOS THERAPEUTICS INC | 3.4% | $59.2m | 2,162,671 | 0% | held | |
| 11 | CRINETICS PHARMACEUTICALS INC | 3.3% | $56.2m | 1,875,209 | 10% | added | |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.1% | $52.4m | 1,950,332 | 0% | held |
| 13 | IMMU IMMUNOMEDICS INC | 2.5% | $43.1m | 3,021,466 | -3% | reduced | |
| 14 | ARVN ARVINAS INC | Healthcare | 2.3% | $40.3m | 3,138,412 | 0% | held |
| 15 | RA PHARMACEUTICALS INC | 2.0% | $34.0m | 4,858,260 | 26% | added | |
| 16 | TGTX TG THERAPEUTICS INC | Healthcare | 2.0% | $33.6m | 8,198,337 | 0% | held |
| 17 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.7% | $28.5m | 1,441,070 | 0% | held | |
| 18 | MNTA MOMENTA PHARMACEUTICALS INC | 1.6% | $28.2m | 2,558,357 | 64% | added | |
| 19 | DICERNA PHARMACEUTICALS INC | 1.5% | $26.3m | 2,456,669 | -38% | reduced | |
| 20 | EIGER BIOPHARMACEUTICALS INC | 1.4% | $24.5m | 2,415,458 | – | new | |
| 21 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.4% | $24.1m | 2,720,452 | 143% | added |
| 22 | MRNA MODERNA INC | Healthcare | 1.3% | $23.1m | 1,514,326 | – | new |
| 23 | KALA PHARMACEUTICALS INC | 1.3% | $22.2m | 4,537,478 | 115% | added | |
| 24 | SCPHARMACEUTICALS INC | 0.6% | $10.7m | 2,857,143 | 0% | held | |
| 25 | PROTEON THERAPEUTICS INC | 0.2% | $3.0m | 1,337,462 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.